Wir sind mit live! Mehr erfahren
IRTC-Symbol

iRhythm Holdings

108,66 USD
-0,69
0,63 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
Vor Börsenbeginn
Nachbörslich
108,66
0,00
0 %
1 Tag
-0,63 %
5 Tage
1,44 %
1 Monat
-2,83 %
3 Monate
-5,8 %
6 Monate
-11,38 %
Seit Jahresbeginn
-37,99 %
1 Jahr
-39,97 %
5 Jahre
54,81 %
10 Jahre
317,12 %
 

Profil: iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

Mitarbeiter: 2.400

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 39,1 %
Neutral 60,9 %
Negativ 0 %
Neutral
GlobeNewsWire
gestern
iRhythm Holdings to Report Third Quarter 2026 Financial Results on November 5, 2026
SAN FRANCISCO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will release financial results for the third quarter 2026 after the close of trading on Thursday, November 5, 2026. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.
iRhythm Holdings to Report Third Quarter 2026 Financial Results on November 5, 2026
Neutral
PRNewsWire
vor 3 Tagen
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Neutral
GlobeNewsWire
vor 10 Tagen
iRhythm Holdings Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Patient Data Is Exposed
Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from a reported data breach at iRhythm Holdings, Inc.
iRhythm Holdings Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Patient Data Is Exposed
Neutral
GlobeNewsWire
vor 11 Tagen
iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care
SAN FRANCISCO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (Nasdaq: IRTC) today announced that it completed the previously announced acquisition of Vital Connect, Inc. ("VitalConnect"), a leader in wearable biosensor technology and ambulatory cardiac monitoring.
iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care
Neutral
GlobeNewsWire
vor 14 Tagen
iRhythm Provides Update on Cybersecurity Incident Previously Disclosed in June 2026
Following completion of the forensic investigation, company begins notifying impacted individuals Following completion of the forensic investigation, company begins notifying impacted individuals
iRhythm Provides Update on Cybersecurity Incident Previously Disclosed in June 2026
Neutral
GlobeNewsWire
vor 19 Tagen
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
NEW YORK, Sept. 27, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of  iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders.
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
Positiv
Zacks Investment Research
vor 24 Tagen
Here's Why You Should Retain IRTC Stock in Your Portfolio for Now
iRhythm's Q2 momentum, AI-driven predictive care and deeper EHR integration support growth, though reimbursement pressures remain.
Here's Why You Should Retain IRTC Stock in Your Portfolio for Now
Positiv
Zacks Investment Research
letzten Monat
Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?
iRhythm's Q2 revenue growth, margin expansion and record free cash flow strengthen its case, but reimbursement and regulatory risks remain elevated.
Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?
Neutral
GlobeNewsWire
letzten Monat
iRhythm Holdings to Participate in Wells Fargo 21st Annual Healthcare Conference
SAN FRANCISCO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference.
iRhythm Holdings to Participate in Wells Fargo 21st Annual Healthcare Conference
Positiv
Seeking Alpha
letzten Monat
iRhythm: The Algorithmic Margin Inflection Changes The Story
iRhythm Technologies is evolving from a cardiac patch producer to a comprehensive cardiac monitoring platform, leveraging software and workflow integration for a competitive advantage. Q2 2026 marked a financial inflection: 20.1% revenue growth, 72.8% gross margin, and adjusted EBITDA margin expansion to 19.3%, with raised full-year guidance and record free cash flow. The ZEUS platform's FDA clearance enables significant margin leverage, reducing clinician review time by 50% and targeting $100 million in cost savings over five years.
iRhythm: The Algorithmic Margin Inflection Changes The Story
Kursdiagramme mit Lightweight Charts™ umgesetzt